Guest Editors
Emirhan Harbi
Biruni University, Biruni University Advanced Technology and Research (B@MER), Faculty of Medicine
Emirhan Harbi is a researcher in the Department of Nuclear Medicine at Istinye University Gaziosmanpasa Hospital in Istanbul, Türkiye, and a student in the Department of Molecular Biology and Genetics at Biruni University. His research focuses on nuclear medicine, molecular imaging, theranostics, and cancer biology, with particular interests in targeted radionuclide therapy for neuroendocrine tumors and gliomas. His work encompasses both preclinical and clinical research, including molecular imaging and theranostic approaches targeting PSMA, FAP, and somatostatin receptors. He has authored peer-reviewed publications on molecular imaging, neuro-oncology, and nuclear medicine and serves as a peer reviewer for numerous international scientific journals.
Refik Bilgin
Istinye University, Department of Nuclear Medicine
Dr. Refik Bilgin completed his medical degree at Dokuz Eylül University Faculty of Medicine. He subsequently completed his residency at the Nuclear Medicine Clinic of Şişli Hamidiye Etfal Training and Research Hospital, earning the title of Nuclear Medicine Specialist. Throughout his career, he has served at leading healthcare institutions in Turkey. For the past six years, he has provided care to patients as a nuclear medicine specialist at Yeni Yüzyıl University Gaziosmanpaşa Hospital and İstinye University Gaziosmanpaşa Hospital. With more than 10 years of professional experience, he has focused particularly on FDG, PSMA, and DOTA-SSA PET-CT imaging techniques, as well as Lutetium-177 and Actinium-225 therapies, developing advanced expertise in these areas. More recently, in collaboration with Emirhan Harbi, he has conducted various molecular imaging and nuclear medicine research studies involving patients with glial and neuroendocrine tumors.
Collection Overview
Despite significant advances in molecular biology, neuroimaging, and targeted therapies, glioblastoma remains one of the most aggressive and difficult-to-treat primary brain tumors. Recent developments in molecular imaging and theranostics, including amino acid PET, PSMA PET, PET/MRI, radiomics, and targeted radionuclide therapy, are transforming the diagnosis, characterization, and management of glioblastoma. These technologies not only improve disease detection and treatment planning but also create new opportunities for precision medicine and translational research.
This Topical Collection aims to showcase the latest experimental and clinical methodologies advancing molecular imaging and theranostic applications in glioblastoma. The collection welcomes video articles demonstrating imaging protocols, radiopharmaceutical development, image analysis techniques, radionuclide therapy workflows, dosimetry methods, and emerging technologies that support precision neuro-oncology.
By bringing together experts in nuclear medicine, neuro-oncology, radiology, medical physics, and translational cancer research, this Topical Collection seeks to provide a comprehensive methodological resource that promotes reproducibility, interdisciplinary collaboration, and the clinical translation of innovative imaging and theranostic strategies.